BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

29 related articles for article (PubMed ID: 27341997)

  • 1. The Relationship Between Metformin and Serum Prostate-Specific Antigen Levels.
    Jayalath VH; Ireland C; Fleshner NE; Hamilton RJ; Jenkins DJ
    Prostate; 2016 Nov; 76(15):1445-53. PubMed ID: 27403913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18.
    Bello D; Webber MM; Kleinman HK; Wartinger DD; Rhim JS
    Carcinogenesis; 1997 Jun; 18(6):1215-23. PubMed ID: 9214605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin: A Dual-Role Player in Cancer Treatment and Prevention.
    Galal MA; Al-Rimawi M; Hajeer A; Dahman H; Alouch S; Aljada A
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating synergistic effects of metformin and simvastatin on ovarian cancer cells.
    Mikhael S; Kurdi A; Khoueiry-Zgheib N; Tahtouh R; Nasr R; Hilal G
    PLoS One; 2024; 19(3):e0298127. PubMed ID: 38489280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin and Cancer Hallmarks: Molecular Mechanisms in Thyroid, Prostate and Head and Neck Cancer Models.
    Morale MG; Tamura RE; Rubio IGS
    Biomolecules; 2022 Feb; 12(3):. PubMed ID: 35327549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin exerts anti-AR-negative prostate cancer activity via AMPK/autophagy signaling pathway.
    Chen C; Wang H; Geng X; Zhang D; Zhu Z; Zhang G; Hou J
    Cancer Cell Int; 2021 Aug; 21(1):404. PubMed ID: 34399755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Mevalonate Pathway, a Metabolic Target in Cancer Therapy.
    Guerra B; Recio C; Aranda-Tavío H; Guerra-Rodríguez M; García-Castellano JM; Fernández-Pérez L
    Front Oncol; 2021; 11():626971. PubMed ID: 33718197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced glycosylation end products (AGEs) controls proliferation, invasion and permeability through orchestrating ARHGAP18/RhoA pathway in human umbilical vein endothelial cells.
    Li X; Tao Y; Wang X; Wang T; Liu J
    Glycoconj J; 2020 Apr; 37(2):209-219. PubMed ID: 32016689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disparities in prostate cancer incidence and mortality rates: Solvable or not?
    Badal S; Aiken W; Morrison B; Valentine H; Bryan S; Gachii A; Ragin C
    Prostate; 2020 Jan; 80(1):3-16. PubMed ID: 31702061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effect of
    Arroyo-Acevedo JL; Rojas-Armas JP; Herrera-Calderón O; Chávez-Asmat R; Justil-Guerrero HJ; Aguilar-Carranza C; Enciso-Roca E; Tinco-Jayo JA; Yuli-Posadas RÁ; Franco-Quino C; Chumpitaz-Cerrate V
    Onco Targets Ther; 2019; 12():6555-6562. PubMed ID: 31616164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin alters H2A.Z dynamics and regulates androgen dependent prostate cancer progression.
    Tyagi M; Cheema MS; Dryhurst D; Eskiw CH; Ausió J
    Oncotarget; 2018 Dec; 9(97):37054-37068. PubMed ID: 30651935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant attenuation of HMG-CoA reductase expression potentiates the cancer cell growth-inhibitory effect of statins and expands their efficacy in tumor cells with epithelial characteristics.
    Ishikawa T; Hosaka YZ; Beckwitt C; Wells A; Oltvai ZN; Warita K
    Oncotarget; 2018 Jun; 9(50):29304-29315. PubMed ID: 30034619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin: A Bridge between Diabetes and Prostate Cancer.
    Zingales V; Distefano A; Raffaele M; Zanghi A; Barbagallo I; Vanella L
    Front Oncol; 2017; 7():243. PubMed ID: 29075616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of metformin and simvastatin on the growth of LNCaP and RWPE-1 prostate epithelial cell lines.
    Pennanen P; Syvälä H; Bläuer M; Savinainen K; Ylikomi T; Tammela TLJ; Murtola TJ
    Eur J Pharmacol; 2016 Oct; 788():160-167. PubMed ID: 27341997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of simvastatin, acetylsalicylic acid, and rosiglitazone on proliferation of normal and cancerous prostate epithelial cells at therapeutic concentrations.
    Murtola TJ; Pennanen P; Syvälä H; Bläuer M; Ylikomi T; Tammela TL
    Prostate; 2009 Jun; 69(9):1017-23. PubMed ID: 19301305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1- and Ripk3-dependent necrosis in C4-2B osseous metastatic castration-resistant prostate cancer cells.
    Babcook MA; Sramkoski RM; Fujioka H; Daneshgari F; Almasan A; Shukla S; Nanavaty RR; Gupta S
    Cell Death Dis; 2014 Nov; 5(11):e1536. PubMed ID: 25412314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of high and low-dose simvastatin on prostate epithelial cells: the role of LDL.
    Murtola TJ; Syvälä H; Pennanen P; Bläuer M; Solakivi T; Ylikomi T; Tammela TL
    Eur J Pharmacol; 2011 Dec; 673(1-3):96-100. PubMed ID: 22040920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The importance of LDL and cholesterol metabolism for prostate epithelial cell growth.
    Murtola TJ; Syvälä H; Pennanen P; Bläuer M; Solakivi T; Ylikomi T; Tammela TL
    PLoS One; 2012; 7(6):e39445. PubMed ID: 22761797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colorectal and Prostate Cancer Risk in Diabetes: Metformin, an Actor behind the Scene.
    Anwar MA; Kheir WA; Eid S; Fares J; Liu X; Eid AH; Eid AA
    J Cancer; 2014; 5(9):736-44. PubMed ID: 25368673
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.